Loading...
Market
Which geographical regions will be included in the Phase 3 trial for DengiAll vaccine by December 31, 2024?
2
Resolution / Starting Odds
Only Haryana • 25%
Multiple states in Northern India • 25%
Multiple states across India • 25%
International regions included • 25%
Official announcement from ICMR or Panacea Biotec
Story
ICMR and Panacea Biotec Start Phase 3 Trial for DengiAll, India's First Indigenous Dengue Vaccine
Aug 14, 2024, 12:15 PM
The Indian Council of Medical Research (ICMR) and pharmaceutical company Panacea Biotec have initiated the first-ever Phase 3 clinical trial for a dengue vaccine in India. The indigenous vaccine, named DengiAll, marks a significant advancement in the fight against dengue. The trial began with the administration of the first dose in Rohtak, Haryana, ahead of India's Independence Day 2024. This development comes as dengue cases remain a concern in India, with 289,235 cases and 485 deaths reported in 2023, according to the National Centre for Vector Borne Diseases Control Programme.
View original story
Similar markets
UK • 14%
USA • 14%
Germany • 14%
France • 14%
Japan • 14%
Australia • 14%
Other • 14%
United States • 25%
European Union • 25%
India • 25%
Other • 25%
Kenya • 25%
Tanzania • 25%
Uganda • 25%
Other • 25%
Yes • 50%
No • 50%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
None • 25%
Europe • 25%
Asia • 25%
Both Europe and Asia • 25%
Africa • 25%
Asia • 25%
Latin America • 25%
Other • 25%
0 • 25%
1 to 5 • 25%
6 to 10 • 25%
More than 10 • 25%
Kenya • 25%
Uganda • 25%
Tanzania • 25%
Other • 25%
Kenya • 25%
Uganda • 25%
Tanzania • 25%
Other • 25%
UK • 14%
USA • 14%
Germany • 14%
France • 14%
Japan • 14%
Australia • 14%
Other • 14%